Reported is a 12-year follow-up of a group of 443 healthy elderly participants that were supplemented with selenium and coenzyme Q10 for four years. After 12 years a significantly reduced CV mortality could be seen in those supplemented with selenium and coenzyme Q10, with a CV mortality of 28.1% in the active treatment group, and 38.7% in the placebo group. Even after twelve years we observed a significantly reduced risk for CV mortality in this group, as well as in subgroups of patients with diabetes, hypertension, ischemic heart disease or impaired functional capacity. The results thus validate the results obtained in the 10-year evaluation.
The protective action was not confined to the intervention period 12 years prior, but persisted during the follow-up period. The mechanisms behind this effect remain to be fully elucidated, although various effects on cardiac function, oxidative stress, fibrosis and inflammation have previously been identified.
Read more at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894963/